We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Afamelanotideis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Afamelanotide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 2010–2023 with a typical study size of 70 participants.
Based on 10 studies · 2 RCTs · 293 total participants
Confidence
LowBy outcome
Afamelanotide has an evidence score of 5/10 — moderate evidence based on 10 indexed studies. A synthetic α-melanocyte-stimulating-hormone (α-MSH) analogue and melanocortin-1-receptor (MC1R) agonist that drives eumelanin production. IMPORTANT: distinguish two very different things. (1) The PRESCRIPTION DRUG afamelanotide (Scenesse) is a 16 mg subcutaneous implant placed by a clinician, FDA-approved (2019) and EMA-approved (2014) to prevent phototoxicity in adults with erythropoietic protoporphyria (EPP) — backed by genuine Phase 3 RCTs. (2) Grey-market 'melanotan I' injected for cosmetic tanning is the SAME molecule sold unregulated, of unknown purity/dose, and is unsafe — associated with mole/nevus changes and is not a supplement. This entry covers the drug honestly; it is not a recommendation to self-inject. Representative study: PMID 26132941.
The commonly studied dose of Afamelanotide is Approved EPP regimen is a single 16 mg controlled-release SUBCUTANEOUS IMPLANT inserted by a clinician approximately every 60 days. There is NO consumer dose — afamelanotide is a prescription drug administered in a clinical setting, not a self-dosed supplement.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Melanotan-1
Mostly mechanism / observationalA grey-market injectable α-MSH analog sold for tanning ('the Barbie drug'). Chemically it is the SAME peptide as the approved drug afamelanotide (Scenesse). Honest appraisal: as an unregulated tanning injectable it has no efficacy/safety validation; its evidence base belongs to the regulated form for a rare blood disorder. Research-use-only.
SNAP-8
Last reviewed June 2026 · evidence from 10 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Afamelanotide (Scenesse)
A synthetic α-melanocyte-stimulating-hormone (α-MSH) analogue and melanocortin-1-receptor (MC1R) agonist that drives eumelanin production. IMPORTANT: distinguish two very different things. (1) The PRESCRIPTION DRUG afamelanotide (Scenesse) is a 16 mg subcutaneous implant placed by a clinician, FDA-approved (2019) and EMA-approved (2014) to prevent phototoxicity in adults with erythropoietic protoporphyria (EPP) — backed by genuine Phase 3 RCTs. (2) Grey-market 'melanotan I' injected for cosmetic tanning is the SAME molecule sold unregulated, of unknown purity/dose, and is unsafe — associated with mole/nevus changes and is not a supplement. This entry covers the drug honestly; it is not a recommendation to self-inject.
Two Phase 3 RCTs back the approved implant for EPP phototoxicity with modest but consistent effects; benefit beyond EPP rests on one vitiligo RCT plus reviews, and grey-market use is unsafe.
Afamelanotide (Scenesse; developmental code CUV1647; Nle4-D-Phe7-α-MSH) is a synthetic, more stable and more potent analogue of α-melanocyte-stimulating hormone. It binds the melanocortin-1 receptor (MC1R) on melanocytes; MC1R signaling raises intracellular cAMP, which increases synthesis of eumelanin (the photoprotective brown-black pigment) and also induces antioxidant activity, enhances DNA-repair processes, and modulates inflammation. Crucially, this pigmentation is induced independently of UV exposure, which is what makes it useful in a disease where any light triggers pain.
The approved drug is delivered as a biodegradable, controlled-release SUBCUTANEOUS IMPLANT containing 16 mg of afamelanotide, inserted by a healthcare professional roughly every 60 days. Its one approved indication is the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP) — a rare inherited photodermatosis (ferrochelatase deficiency → protoporphyrin IX accumulation) in which sunlight causes excruciating burning pain. The evidence base here is real and unusual for a 'peptide': two multicenter, randomized, double-blind, placebo-controlled Phase 3 trials (published together in the New England Journal of Medicine, 2015) showed afamelanotide significantly increased pain-free time in direct sunlight, reduced phototoxic reactions, and improved quality of life. The absolute effect sizes were modest but consistent across the EU and US trials and a further confirmatory Phase 3 study (CUV039). On that basis it was approved by the EMA (2014) and FDA (2019). Long-term observational data also suggest a dose-dependent improvement in EPP-related liver-function markers.
Beyond EPP, afamelanotide has been tested in other dermatology indications with mixed/smaller evidence. A randomized multicenter trial in non-segmental vitiligo found that adding the implant to narrowband UV-B phototherapy produced faster, more complete repigmentation than phototherapy alone — promising but a single combination-therapy RCT, strongest in darker skin phototypes. Smaller studies and case series describe use in polymorphic light eruption, solar urticaria, Hailey-Hailey disease, and acne; these are not approved uses and the evidence is preliminary.
The critical safety distinction: the SAME molecule is sold on the grey market as 'melanotan I' (and its sibling melanotan II) for cosmetic tanning, injected by users without any purity, sterility, or dosing control. Multiple national health agencies have issued warnings; case reports link unregulated melanotan use to darkening and change of existing moles, eruptive dysplastic nevi, and (in a handful of reports) melanomas arising in pre-existing moles — so the regulated drug's reassuring safety record should NOT be read across to unregulated tanning use. Afamelanotide does not replace photoprotection, and it is a prescription product, not a dietary supplement.
A synthetic α-MSH analogue that binds MC1R on melanocytes more potently and stably than the natural hormone, raising intracellular cAMP.
MC1R signaling increases production of eumelanin, the photoprotective brown-black pigment — and does so without requiring UV exposure, which is essential in a disease where any light causes pain.
Beyond pigmentation, MC1R activation induces antioxidant activity, enhances DNA-repair processes, and modulates inflammation — proposed contributors to its photoprotective effect.
How Afamelanotide works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Approved EPP regimen is a single 16 mg controlled-release SUBCUTANEOUS IMPLANT inserted by a clinician approximately every 60 days. There is NO consumer dose — afamelanotide is a prescription drug administered in a clinical setting, not a self-dosed supplement.
Can be taken without food
| Form | Type |
|---|---|
| 💊16 mg subcutaneous controlled-release implant (prescription, clinician-administered) | Recommended |
Only the implant has regulatory approval and trial evidence. Injectable 'melanotan I' sold online is the same molecule but unregulated, unverified, and unsafe — not an alternative.
Minimum: 8 weeks
Optimal: 24 weeks
Cycling: Not required
Note: Implant placed by a clinician roughly every 60 days; in EPP it is typically given across the higher-sunlight months. Not a consumer product — there is no self-administration timing guidance.
Dose-response data unavailable. The current published research for Afamelanotide does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
In two Phase 3 RCTs, EPP patients on afamelanotide had significantly longer pain-free direct-sun exposure, fewer phototoxic reactions, and improved quality of life versus placebo. Absolute effects were modest but consistent.
Nearly all users develop diffuse hyperpigmentation — the intended pharmacology in EPP, and the reason the same molecule is abused for cosmetic tanning.
Adding the implant to narrowband UV-B produced faster, more complete repigmentation than phototherapy alone in one RCT, strongest in darker skin phototypes — promising but a single combination study and not an approved use.
Most common adverse reactions in trials were headache and reactions at the implant site; serious adverse events were generally not drug-related.
Unregulated 'melanotan I' injected for tanning has been linked in case reports to darkening of existing moles, eruptive dysplastic nevi, and rare melanomas — a harm signal that should NOT be read across to the supervised drug.
Avoid — safety in pregnancy and lactation is not established.
Requires specialist assessment and skin-surveillance; melanocyte-stimulating effects warrant caution and monitoring.
Do not self-inject grey-market melanotan I. It is unregulated, of unknown purity and dose, and linked to mole changes and rare melanoma. The approved drug's safety record does not transfer to unregulated vials.
Approval is for adults; pediatric use is not established — manage only via a porphyria specialist.
Used deliberately with narrowband UV-B in vitiligo research, but combining induced pigmentation with other photosensitizers or light treatments should be managed by a clinician.
As with any subcutaneous implant procedure, bleeding/bruising at the implant site is more likely on blood thinners; a clinical consideration at placement.
Tip: Expected pharmacology (the intended effect in EPP); near-universal. Not harmful in itself but cosmetically significant.
Tip: Among the most common adverse reactions in trials; usually self-limited.
Tip: Local reaction at the subcutaneous implant site; generally mild.
Tip: Reported in trials; generally transient.
Tip: Reported with UNREGULATED melanotan tanning use — darkening moles, new dysplastic nevi, rare melanomas. Any changing mole needs urgent dermatology review. This risk attaches to unsupervised use, not the supervised implant.
Timing is flexible for Afamelanotide — consistent daily use matters more than the time of day. Administered as a long-acting subcutaneous implant every ~60 days by a healthcare professional, typically before/through the sunlight season in EPP.
Afamelanotide should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are diffuse skin hyperpigmentation, headache, implant-site reaction (pain, erythema). Use caution if any of these apply to you: Use outside a prescriber's care — afamelanotide is a prescription drug, not a self-administered supplement; Pregnancy and breastfeeding (not established as safe); Personal history of melanoma or numerous/atypical moles without specialist oversight.
A topical 'anti-wrinkle' cosmetic peptide (acetyl octapeptide-3), an elongated relative of argireline that is marketed to relax expression lines by mimicking a SNARE-complex fragment. Honest appraisal: independent human evidence for SNAP-8 specifically is minimal; most support is manufacturer data and extrapolation from argireline. A topical cosmetic ingredient, not a supplement or drug.